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ABSTRACT:
p53 is well known as the “guardian of the genome” for differentiated and neoplastic 
cells. p53 induces cell-cycle arrest and cell death after DNA damage and thus 
contributes to the maintenance of genomic stability. In addition to this tumor 
suppressor function for pro-oncogenic cells, p53 also plays an important role as 
the central regulator of stress response by maintaining cellular homeostasis at the 
molecular and biochemical level. p53 regulates aerobic respiration at the glycolytic 
and oxidative phosphorylation (OXPHOS) steps via transcriptional regulation of 
its downstream genes TP53-induced glycolysis regulator (TIGAR) and synthesis 
of cytochrome c oxidase (SCO2). p53 negatively regulates glycolysis through 
activation of TIGAR (an inhibitor of the fructose-2,6-bisphosphate). On the contrary 
p53 positively regulates OXPHOS through upregulation of SCO2, a member of the 
COX-2 assembly involved in the electron-transport chain. It is interesting to notice 
that p53 antagonistically regulates the inter-dependent glycolytic and OXPHOS 
cycles. It is important to understand whether the p53-mediated transcriptional 
regulation of TIGAR and SCO2 is temporally segregated in cancer cells and what is 
the relation between these paradoxical regulations of glycolytic pathway with the 
tumor suppressor activity of p53. In this review we will elucidate the importance 
of p53-mediated regulation of glycolysis and OXPHOS and its relation with the 
tumor suppressor function of p53. Further since cellular metabolism shares 
great relation with the process of aging we will also try and establish the role of 
p53 in regulation of aging via its transcriptional control of cellular metabolism. 
ABSTRACT
p53 is well known as the “guardian of the genome” 
for differentiated and neoplastic cells. p53 induces cell-
cycle arrest and cell death after DNA damage and thus 
contributes to the maintenance of genomic stability. 
In addition to this tumor suppressor function for pro-
oncogenic cells, p53 also plays an important role as 
the central regulator of stress response by maintaining 
cellular homeostasis at the molecular and biochemical 
level. p53 regulates aerobic respiration at the glycolytic 
and oxidative phosphorylation (OXPHOS) steps via 
transcriptional regulation of its downstream genes TP53-
induced glycolysis regulator (TIGAR) and synthesis of 
cytochrome c oxidase (SCO2). p53 negatively regulates 
glycolysis through activation of TIGAR (an inhibitor 
of the fructose-2,6-bisphosphate). On the contrary p53 
positively regulates OXPHOS through upregulation of 
SCO2, a member of the COX-2 assembly involved in the 
electron-transport chain. It is interesting to notice that p53 
antagonistically regulates the inter-dependent glycolytic 
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whether the p53-mediated transcriptional regulation of 
TIGAR and SCO2 is temporally segregated in cancer 
cells and what is the relation between these paradoxical 
regulations of glycolytic pathway with the tumor 
suppressor activity of p53. In this review we will elucidate 
the importance of p53-mediated regulation of glycolysis 
and OXPHOS and its relation with the tumor suppressor 
function of p53. Further since cellular metabolism shares 
great relation with the process of aging we will also try 
and establish the role of p53 in regulation of aging via its 
transcriptional control of cellular metabolism. 
INTRODUCTION
p53, often referred to as the “guardian of the 
genome,” is the most commonly mutated gene in human 
cancer [1]. In response to DNA damage or other types 
of stress, p53 acts as a sequence-specific transcription 
factor and orchestrates the appropriate cellular response 
by inducing cell-cycle arrest, apoptosis, senescence, or 
differentiation [2, 3]. Thus p53 mediates cell response 
to various cellular stressors and thus plays a pivotal 
role in tumorogenesis, cell-death and survival [4]. In 
cells experiencing DNA-damage, hypoxia, genotoxicity, 
cytotoxicity, and oxidative stress, p53 dissociates from 
its ubiquitin ligase MDM2, via various post-translational 
modifications  which  promote  its  stabilization  and 
activation [5]. Active p53 migrates to the nucleus and 
activates the expression of its down-stream genes involved 
in cell-cycle regulation, DNA repair, senescence, and cell 
death [1]. Recent findings indicated that p53 plays an 
important role in the regulation of cellular metabolism, 
specifically glycolysis and OXPHOS in cancerous cells. 
Glucose metabolism is a major step in the development 
and sustenance of a variety of cancers in human body. 
However, how p53 regulates metabolism and the relation 
of this newly discovered role of p53 with its universal 
role of tumor suppressor is not known. The regulation of 
cellular metabolism determines the physiological response 
of cancer cells to nutrients and oxygen and accordingly 
chooses to promote cell-proliferation, growth and survival 
[6]. In this review, we will try to elucidate the complex 
network of p53 regulation of cellular metabolism and p53 
tumor suppressor activity.
P53 AND THE WARBURG EFFECT 
Otto Warburg established that cancer cells 
undergo high rates of aerobic glycolysis due to lack of 
mitochondrial oxidative phosphorylation [7, 8]. This 
effect termed as the “Warburg effect” is one of the prime 
causes of malignancy. The cellular metabolism in cancer 
cells is dependent upon key cancer-related transcription 
factors, such as p53 and HIF-1 [8, 9]. p53 is now known 
to positively upregulate OXPHOS by transcribing SCO2 
(a COX2 assembly protein) and p53 down-regulates 
glycolysis by transcribing TIGAR (an inhibitor of the 
fructose-2,6-bisphosphate) [8-11]. Recent research shows 
that loss of p53 enhances aerobic glycolysis in cancer cells, 
resulting in the development of a more aggressive and 
highly metastatic forms of cancer [12]. Most of the cancer 
forms are linked with a physiological phenomenon termed 
“hypoxia”, thus expression of HIF-1 plays an important 
part in the regulation of cancer-cell metabolism [13]. HIF-
1 directly influences Warburg effect by transcriptional 
regulation of glycolytic enzymes such as HK2, PDK1, 
and LDH-A [8, 14]. Considering the importance of p53 
in tumor suppression and the high mutation rate of p53 
(>50%) in human tumors, recent findings suggest that the 
mutation of the p53 gene and the resultant loss of function 
of the p53 protein in tumors could be an important genetic 
change contributing to the Warburg effect.
ROLE OF P53 IN REGULATING 
GLYCOLYSIS
p53 is now known to not only drive the damaged 
cells to undergo apoptosis but also coordinates how 
cells use nutrients to preserve their survival. The role 
of p53 in the negative regulation of cellular glycolysis 
is now reported [15]. The p53 downstream gene TIGAR 
(TP53-induced  glycolysis and apoptosis  regulator), 
is a direct transcriptional target of p53 and it alters the 
pathway in which cancer cells use cellular glucose. 
TIGAR shares functional sequence similarities with the 
bis-phosphatase domain (FBPase-2) of the bi-functional 
enzyme  PFK-2/FBPase-2  (6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase), which degrades fructose-
2,6-bisphosphate (Fru-2,6-P2). Fru-2,6-P2 induces 
6-phospho-1-kinase for conversion of fructose-6-
phosphate to fructose-1,6-bisphosphate at the third step of 
the cellular glycolysis reaction. The decrease in the Fru-
2,6-P2 level induces the formation of fructose-6-phosphate. 
TIGAR causes a significant reduction in the cellular Fru-
2,6-P2 levels and thereby blocks glycolysis at this step. 
TIGAR directs the metabolism of cellular glucose through 
pentose phosphate pathway thus producing the redox-
active reactive oxygen species (ROS) quenching NADPH 
[15]. TIGAR is direct transcriptional target of p53 and p53 
has two binding sites in the TIGAR promoter named BS1 
and BS2. BS1 shows little binding affinity towards p53 
and lies upstream the +1 transcription start site, whereas 
BS2 shows strong binding affinity towards p53 and lies 
in the first intron downstream the +1 transcription start 
site [15]. Since TIGAR activates the pentose-phosphate 
pathway and causes an increase in the NADPH generation, 
this causes an increase in cellular glutathione (GSH) 
levels, which acts as ROS scavengers. Bensaad et al12 
reported that overexpression of TIGAR cDNA in cancer 
cells led to ROS quenching and protection from p53-
mediated apoptosis as a result of genotoxic stress and 
DNA-damage [16]. Further, it has been reported that Oncotarget 2011; 2:  948 - 957 950 www.impactjournals.com/oncotarget
TIGAR-mediated increase in the pentose-phosphate-
pathway also led to substantial increase in the cellular 
DNA repair [17]. Increase in the cellular NADPH levels 
blocks the apoptotic effector caspases like caspase-2 and 
caspase-9 [18], thus resulting in neutralization of p53 
apoptotic response. 
ROS, generated under conditions of genotoxicity 
and mitochondrial stress, transcriptionally activate p53, 
facilitate its nuclear entry, and inhibits p53 binding with 
MDM2 [19]. It appears that the sequence of cellular 
events involving activation of p53, TIGAR upregulation, 
inhibition of glycolysis, increase in pentose-phosphate 
pathway, generation of ROS scavenging GSH and 
NADPH are a part of the p53 feedback loop to neutralize 
ROS-induced cell death. Further, this pathway might 
help in DNA and cellular damage repair in cancer cells 
suffering from repairable dose of cellular/genotoxic insult 
[15]. Interestingly, the mechanism behind the choice made 
by p53 to drive cells for apoptosis or to facilitate cellular 
repair through TIGAR pathway is unknown. Collectively, 
these observations suggest that the effects of p53 on 
metabolism are responses to environmental conditions.
ROLE OF P53 IN THE REGULATION OF 
OXIDATIVE PHOSPHORYLATION
Oxidative phosphorylation (OXPHOS) is the 
mitochondrial pathway of energy generation which 
succeeds tricarboxylic acid (TCA) cycle to produce 
adenosine triphosphate (ATP) through electron transport-
coupled OXPHOS [6]. p53 is now shown to directly 
regulate OXPHOS in mice and human cancer cell lines 
through transcriptional upregulation of its downstream 
gene synthesis of cytochrome c oxidase (SCO2) [10]. p53 
directly binds to SCO2 promoter and induces an increase 
in its mRNA and protein level. SCO2 is a COX assembly 
protein required for transfer of copper to the cytochrome 
c oxidase (COX) complex. COX, the inner mitochondrial 
membrane protein comprises of thirteen subunits (three 
mitochondrial-encoded subunits and ten nuclear-encoded 
subunits). SCO proteins (SCO1 and SCO2) are part of 
the COX holo-enzymes and are required for transfer of 
copper from COX17 to COX [20]. SCO2 acts upstream 
of SCO1 in this pathway, and is indispensable for COX 
II synthesis [21, 22]. SCO1 and SCO2 gene mutations 
in humans results in poor formation of COX and COX 
deficiency. SCO2 mutations result in neonatal encephalo-
cardiomyopathy, spinal muscular atrophy (SMA), neonatal 
hepatic failure, and fatal hypertrophic cardiomyopathy 
[23, 24]. Most of the SCO2 patients carry an E140K 
missense mutation on one allele adjacent to the conserved 
CxxxC motif which regulates the efficiency of SCO2 to 
bind to copper and function as a redox protein [22]. 
SCO2 protein is regulated by p53 thus it can be 
postulated that p53 via SCO2 plays a major role in copper 
homeostasis. Copper is stored in the mitochondrial matrix 
space and mitochondrial inner membrane is impermeable 
to copper transport, thus copper-binding membrane 
proteins are indispensable to the transport of copper 
between the mitochondria and the cytoplasm. In fact, 
severe cellular copper deficiency is observed in patients 
with non-functional SCO2 protein and further wild-type 
SCO2 overexpression complements the copper-deficiency 
phenotype [25]. The transcriptional regulation of SCO2 by 
p53 might also be responsible for p53-mediated regulation 
of  mitochondrial  signals  and  cellular  thiol–disulfide 
oxidoreductase reactions required for oxidation of the 
copper-binding cysteine amino acids in the mitochondrial 
proteins [22].
In human colon cancer cell lines, DLD1 and SW480, 
the overexpression of SCO2 protein increase OXPHOS 
even in presence of p53 mutations suggesting that p53-
mediated regulation of OXPHOS is via SCO2 [10]. In 
HCT116  human  colon  cancer  cell  line,  deficiency  in 
p53 causes low expression of SCO2, resulting in lower 
OXPHOS which is balanced by the increase in glycolysis 
[26]. This suggests that the downregulation of p53-
dependent regulation of SCO2 impairs the mitochondrial 
respiratory chain, causing a shifting of ATP production 
from OXPHOS to glycolysis.
RELATIONSHIP BETWEEN TIGAR, 
SCO2 AND P53-MEDIATED EFFECTOR 
RESPONSES
TIGAR suppresses glycolysis which generates 
necessary NADPH required for the OXPHOS. Thus 
synthesis of TIGAR should down-regulate OXPHOS, 
instead  p53  transcriptionally  synthesizes  another  gene 
SCO2 which up-regulates OXPHOS. It is understandable 
that in order to support p53 and SCO2-mediated increase 
in OXPHOS the cellular glycolytic levels must also be 
high. Thus p53 cannot transcriptionally regulate TIGAR 
and SCO2 at the same time and their regulation via p53 
must be temporally segregated. It is logical to believe 
that p53 might upregulate either TIGAR or SCO2 at one 
point in time depending upon the intensity of the cellular 
and genotoxic stressors; however no data is available to 
support this hypothesis. On basis of the existing literature 
and the cellular outcomes observed upon upregulation of 
TIGAR and SCO2 in cancer cells, the cellular conditions 
which might lead to the synthesis of these genes can be 
predicted. Further, the individual role of TIGAR and 
SCO2 in assisting the tumor suppressor response of p53 
can be hypothesized. 
The effect of TIGAR on cell survival was proposed 
to be cell and context dependent [15]. Interestingly, the 
switch from p53-induced cell-cycle arrest to apoptosis 
following prolonged stress is associated with a decrease 
in expression of both TIGAR and p21WAF1/CIP1, suggesting 
that the induction of the apoptotic response may reflect 
upon the loss of protection by these p53-inducible survival Oncotarget 2011; 2:  948 - 957 951 www.impactjournals.com/oncotarget
signals. TIGAR might be recruited by p53 to induce cell-
cycle arrest in cancer cells undergoing mild cellular and 
genotoxic stress. Most importantly TIGAR has the ability 
to reduce cellular ROS, which is necessary for the p53-
mediated apoptotic response. TIGAR lowers glycolysis 
and  thus  significantly  reduces  the  cellular ATP  level, 
which is crucial for cell division and other housekeeping 
activities. We predict that TIGAR falls into the group of 
genes that are activated by low levels of stress and plays 
a key role in the tumor-suppressor function of p53. p53 
tumor suppressor provides an opportunity of survival 
and resurrection to the cancer cells which are suffering 
for repairable doses of cellular/genotoxic insult through 
upregulation of TIGAR protein. A model has been 
proposed which explains the putative mechanism of the 
p53-mediated transcriptional regulation of TIGAR in 
inducing the cell-cycle arrest response in cancer cells 
(Figure 1a). 
SCO2, on the other hand, increases OXPHOS and 
supports cell division and most importantly increase the 
ATP supply to the cancer cells. It is a well-known fact 
that the cellular apoptosis is an ATP-dependent process 
[27]. Further, reactive oxygen species (ROS) is a toxic by-
product of the mitochondrial energy production pathway, 
oxidative phosphorylation (OXPHOS), in cancer cells 
[28]. Since p53 increases OXPHOS via SCO2, it is 
logical to assume that p53-mediated SCO2 upregulation 
will eventually lead to accumulation of cellular ROS. 
ROS plays a major role in the progressive accumulation of 
cellular and tissue damage in neoplastic cells [29]. Further 
ROS also provides an efficient pathway of eliminating 
cancerous cells through apoptosis [29]. In addition to 
the synthesis of ROS there might be other pathways 
which determine the SCO2- and p53-mediated apoptotic 
response in the cancer cells which are suffering for the 
non-repairable doses of cellular/genotoxic stress. A model 
has been proposed to elucidate the predicted mechanism 
of p53-mediated transcriptional regulation of SCO2 gene 
in cancer cells (Figure 1b). It has become clear that in 
addition to the regulation of cellular metabolism, the p53-
mediated transcriptional regulation of TIGAR and SCO2 
is another tool in the armory of p53 to choose and protect 
cells which are capable of repair and further to effectively 
drive the non-repairable cells towards cellular apoptosis. 
ROLE OF P53 IN METABOLISM AND 
AGING
The metabolic rate of organisms is related with their 
aging process [30]. Aging is dependent and proportional to 
the generation of ROS, a byproduct of cellular metabolism, 
which attack cell constituents and cause damage to 
cellular structures, and ROS is a by-product of metabolic 
reactions. ROS can induce apoptosis in cancer cells [19] 
thus cancer cells try and neutralize cellular oxidative stress 
via activation and upregulation of metabolic machinery 
involved in glycolysis. The crucial steps of this metabolic 
response against ROS production involves activation of 
the (i) pentose phosphate pathway (PPP), which regulates 
the redox status via the NADP+/NADPH ratio and (ii) 
glutathione system [7, 31]. 
Both anaerobic and aerobic glycolysis forms are 
high in cancer cells [8]. p53 is also now linked to regulate 
cellular aging through its newly found role in cellular 
metabolism. In cancer cells, p53-signaling molecule 
AMPK acts as an energy sensor and increases glycolysis 
[32, 33]. AMPK can also activate the tumor suppressor 
p53 in a feed-back loop, thus promoting cellular survival 
and aging [34]. Recent studies by Kawauchi et al. [35, 
36] have revealed that increased glycolysis can enhance 
the O-glycosylation of IKKβ that subsequently triggers the 
NF-κB signaling. Growing literature shows that the IKK/
NF-κB signaling pathway is involved in the carcinogenesis 
[37-39] but many observations also demonstrate that NF-
κB system is activated during the aging process [40]. These 
observations refer to the fundamental role of glycolysis 
in cancer cells but it raises the question of whether p53 
and the glycolytic flux can also regulate NF-κB signaling 
during the aging process. Interestingly, Kawauchi et al. 
Figure 1a: A model depicting the mechanism of p53-mediated regulation of TIGAR gene in cancer cells.
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[35] observed that the glycolysis-dependent activation of 
NF-κB signaling is regulated by tumor suppressor p53 
oncogene. 
Since p53 has a profound effect on metabolism and 
it increases aerobic metabolism and inhibits glycolysis 
[41].  The  O-glycosylation  of  NF-κB  at  its  Ser/Thr 
residues via HBP pathway has revealed the role of p53, 
NF-κB and metabolism in the process of aging [35, 36, 
42]. p53 is now known to negatively regulate the IKK/
NF-κB signaling through p53-dependent regulation of 
glycolysis via TIGAR. High glucose levels increase 
O-GlcNAc of IKKβ at its Ser733 residue, which is an 
inactivating phosphorylation site of the enzyme [35, 36]. 
High glucose levels can also increase the O-GlcNAc 
modification  of  p65,  the  trans-activating  component 
of the NF-κB complex [43]. O-GlcNAc-p65 does not 
bind to its inhibitory protein Iκ-Bα and thus increases 
NF-κB-mediated  transcription.  Thus  regulation  of 
cellular glucose levels and glycolysis by p53 controls 
the  NF-κB-mediated  transcription.  The  p53-mediated 
regulation of TIGAR seems to function in another feed-
back loop since O-GlcNAc-p53 is protected from its 
ubiquitination-mediated degradation [44]. p53 deletions 
and mutations will result in transcriptional inhibition at 
TIGAR promoter, thus an increases the glycolysis and 
the transcriptionally active O-GlcNAc- NF-κB thus the 
development and progression of cancer [39]. It is logical 
to assume that p53 might suppress the NF-κB signaling 
via the inhibition of glycolysis through regulation of 
TIGAR  protein.  NF-κB  signaling  and  glycolysis  are 
involved in pre-mature aging. The anti-aging proteins 
and the p53 c-terminus de-acetylases Sirtuin family of 
proteins, SIRT1 and SIRT6, are powerful inhibitors of 
NF-κB signaling as well. It is established that p53 lies 
at the nexus of the phenomena of aging and cancer [45, 
46]. p53 stabilization in mouse models have resulted in 
resistance to cancer in combination with the development 
of the signs of pre-mature aging [47]. P53 transcriptional 
activity also decreases with increasing age of animals [48]. 
It is believed that decrease in p53 transcriptional activity 
in mammalian systems will lead to increase in glycolysis 
and decrease in OXPHOS, ultimately resulting in a strong 
relation between metabolism and aging. 
P53 AT THE NEXUS OF CELLULAR AGING 
AND SENESCENCE
Cellular senescence is a complexity of aging and 
cancer biology. As malignant tumors can culminate 
individuals in life-termination, evolution has provided 
multicellular organisms with an acquisition of distinctive 
safety device, cellular senescence, to circumvent the 
development. Cellular senescence, a state of irreversible 
growth arrest and cellular aging, an increase in the 
probability of death over survival, both can be triggered 
by multiple mechanisms. Eukaryotic cells have carefully 
devised these checkpoints to limit oncogenic cellular 
proliferation. Senescent cells may remain viable and 
quiescent in culture conditions and in the organisms 
[49] or may be cleared by the phagocytic machinery 
[50]. Senescence and aging are linked since aging is 
accompanied by increase in the volume of senescent 
cells and decrease in the division/regeneration potential 
of the stem-cell pool [51]. The telomere clock is one 
connecting link between senescence and aging. Telomere-
mediated protection against cancer induces senescence 
and/or apoptosis [52, 53]. Telomere-induced senescence 
is now an established anti-neoplastic mechanism [54]. 
In humans, an inverse correlation between telomere 
length and cellular aging and between telomere length 
and aging related diseases is now well established [55, 
56]. Factors which are known to decrease longevity, 
are known to decrease telomerase activity and telomere 
length [57, 58]. Furthermore, human premature aging 
syndromes, like dyskeratosis congenita and aplastic 
anemia, are linked with telomere shortening [59]. Further 
reinforcing the link between the telomere clock and 
Figure 1b: A model depicting the mechanism of p53-mediated regulation of SCO2 gene in cancer cells.
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aging is the observation that mice deficient in telomerase 
activity have short telomeres and age prematurely [60, 
61]. Remarkably, even the first generation of telomerase-
deficient mice already has a shortened lifespan, which 
becomes shorter and shorter in subsequent generations 
[62]. Moreover, telomeres become measurably shorter 
in mice, particularly at very old ages [63]. Finally, mice 
overexpressing telomerase are prone to developing 
tumors [64, 65], thus precluding direct demonstration of 
lifespan extension by telomerase; nonetheless, an increase 
in the lifespan of those few telomerase transgenic mice 
that do not develop cancer has been observed [66]. p53 
plays a critical role in maintaining telomere stability [67]. 
p21Cip1, a direct transcriptional target of p53, has been 
shown to be relevant in the signaling of critically short 
telomeres that leads to aging [68]. p21Cip1 gene deletion 
in mice models has been shown to increase longevity of 
telomerase-deficient mice. Further no tumor formation was 
observed which was paradoxical to the effects observed in 
p53-deficient mice [69]. This data further confirmed that 
p53/p21Cip1-dependent senescence specifically induces 
the pro-aging effect of short telomeres. It is now believed 
that p53-mediates both the pro-aging function of telomere 
shortening [70].
The role of p53 in senescence and aging is not 
clearly established. Recently several transcription factors 
have been identified which can both inhibit senescence 
and induce epithelial-mesenchymal transition (EMT) 
thereby increasing the probability of cancer development 
[71]. Mice programmed to constitutively overexpress 
transcriptionally active mutant p53 have minimal 
probability of tumor development than wild-type mice. 
However, such programmed mice show signs of premature 
aging [72, 73]. Interestingly, mice with increased 
wild-type p53 activity do not exhibit premature aging. 
Super-p53 mice, carrying an extra copy of the entire p53 
gene, show minimal probability of tumor development 
teamed up with a display of normal longevity [74]. Extra 
dose of p53 also increases the antioxidant function of p53 
[16, 75]. The conclusion from these observations can be 
made which is suggestive of the fact that the main role 
of p53 is to eliminate damaged cells, either by triggering 
their self-destruction (via apoptosis) or by stalling them 
out of the proliferative pool (via senescence). During 
repairable doses of cellular insult, p53 induces the 
cell-repair pathways and thus activates the anti-aging 
program which compensates for the pro-aging response 
evoked by p53-mediated apoptosis. Exogenous addition 
of p53 copy can cause reversible cell-cycle arrest and/or 
irreversible senescence. Nutlin-3a (a small molecule that 
activates p53 without causing DNA damage), is unique in 
inducing senescence without making the cells quiescent. 
Interestingly, nutlin-3a inhibits the mTOR (mammalian 
target of rapamycin) pathway, a known member of the 
senescence program. It is recently shown that the negative 
regulators of the mTOR signaling, partially converts 
quiescence into senescence in the nutlin-treated cells. The 
mTOR pathway thus is one of the determining factors 
in facilitating the choice of p53 between the senescence 
and quiescence program in the p53-arrested cells [76, 
77]. Further it has been shown that the p53-induced 
quiescence is in fact a result of suppression of senescence 
by p53. In cancer cells arrested with overexpression 
of p21, the addition of p53 converted senescence into 
quiescence and this suppression of senescence by p53 
was dependent on p53-transcriptional activity. Thus, in 
spite of its ability to induce cell-cycle arrest, p53 can act 
as a suppressor of cellular senescence [33, 78]. p53 can 
promote or retard aging, depending on the context of its 
regulation and activity. p53 can regulate both pro-aging 
and pro-longevity effects by either inducing excessive 
apoptosis/cellular senescence or by eliminating damaged 
or dysfunctional cells via apoptosis/senescence [79]. p53 
also transcriptionally regulates insulin/insulin-like growth 
factor (IGF)-1 involved in the IIS pathway. IIS and one of 
its major intracellular targets, the mTOR pathway, drive 
aging in mice [80]. In general, high IIS/mTOR activity 
is associated with cell proliferation, growth and aging, 
whereas low IIS/mTOR activity is associated with somatic 
maintenance and longevity. In addition, p53 is regulated, 
directly and indirectly (through MDM2), by another major 
component of IIS signaling, the PKB/Akt kinase [81]. 
PKB/Akt signaling in turn is also both pro-aging (through 
the NF-kB transcription factor) and pro-longevity (through 
FOXO transcription factors) [82]. p53 transcriptional 
activity depends mainly on post-translational modifications 
and protein/protein interaction [83]. Even though cancer 
cells have partially lost the capacity to signal senescence 
or apoptosis, these responses can conceivably be engaged 
by exogenous agents like p53-activating drugs and p53-
modulating molecular chaperones [84-86]. 
The p53-dependent association between cellular 
senescence and organismal aging is highly suggestive of 
a causal link between these two processes. The cellular 
factors which trigger senescence also trigger apoptosis and 
cell-cycle arrest which makes it challenging to distinguish 
between the role of these three processes in aging [87]. It 
is interesting to observe that cancer is more frequent in 
old age human beings. The simplest explanation for this 
is that old organisms have accumulated more genetic and 
epigenetic aberrations than young organisms, but this does 
not say anything about the intrinsic susceptibility (that 
is, apart from the accumulation of mutations) of young 
and old organisms to develop cancer. Higher incidence 
of cancer at old ages simply reflects the time needed for 
the accumulation of oncogenic mutations. However, one 
must not neglect that with higher age there is a convenient 
environment for cancer growth. Great progress has been 
made in the last few years in understanding how cells 
limit their proliferative potential and in linking these 
mechanisms to cancer protection and aging. Future 
research will clarify whether therapies that induce Oncotarget 2011; 2:  948 - 957 954 www.impactjournals.com/oncotarget
senescence are useful for cancer treatment, and determine 
their effect on aging. Conversely, treatments that inhibit 
senescence in healthy individuals might slow aspects of 
aging. 
CONCLUSION AND FUTURE DIRECTIONS
In summary, p53’s myriad of functions is beyond 
the tumor suppressor roles of being a protein involved in 
cell-cycle arrest, apoptosis and DNA-repair. However, the 
regulation of p53 has turned out to be highly complex and 
context-dependent. For instance, emerging results suggest 
that p53 has both nuclear and cytoplasmic functions 
[88] which may explain some of the controversial 
observations in transgenic models. p53 is now known 
to regulate stress-induced transcriptional programs that 
manipulate the energy metabolism of cancer cells in 
order to facilitate the tumor suppressor role of p53. The 
mechanisms regulating the opposite cell fates in cancer 
development and organism aging have been exciting cell 
biological topics for years. In particular, a lot of research 
effort has been focused on the role of p53 in the regulation 
of longevity [89, 90]. Furthermore, the role of p53 in the 
regulation of energy metabolism is a promising research 
field [41] which can provide some explanations to the 
puzzles of cancer and aging. It is established that energy 
metabolism is crucial for ever-proliferating cancer cells for 
their continued growth and survival. The activation of p53 
to alternatively regulate the two most important aspects 
of metabolism, glycolysis via TIGAR and OXPHOS 
via SCO2 reveals that there are functions for p53 in the 
regulation of other metabolic diseases. Interestingly, how 
p53 can antagonistically regulate two crucial steps of the 
respiration cycle and the relation of this regulation with 
the well-defined tumor suppressor role of p53 needs to be 
elucidated. 
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